Insights
Search Results
Client Highlights
4.27.26
Wilson Sonsini Advises Nervonik on $52.5 Million Series B Financing
On April 27, 2026, Nervonik, a clinical-stage medical device company developing next-generation peripheral nerve stimulation (PNS) technologies, announced the closing of an oversubscribed $52.5 million Series B financing. The round was led by Amzak Health, with participation from Elevage Medical Technologies, U.S. Venture Partners (USVP), Lumira Ventures, Foothill Ventures, and Shangbay Capital. The proceeds from the financing will support the continued development and commercialization of Nervonik's PNS system, including further development of its proprietary sensing capabilities. Wilson Sonsini Goodrich & Rosati advised Nervonik on the transaction.
Client Highlights
1.13.25
Wilson Sonsini Advises Bolt Medical on Merger with Boston Scientific
On January 8, 2025, Boston Scientific announced it has entered into a definitive agreement to acquire Bolt Medical, the developer of an intravascular lithotripsy (IVL) advanced laser-based platform for the treatment of coronary and peripheral artery disease, for up to $900 million. Wilson Sonsini Goodrich & Rosati advised Bolt Medical on the transaction.
Newsletters
6.10.24
The Life Sciences Report – June 2024
This latest edition features articles on biotech client Siolta Therapeutics, the use of safety and efficacy findings to extend drug exclusivity periods, life sciences venture financings for clients in 2023, and updated USPTO guidance for determining non-obviousness. The newsletter also includes details on the recent LaunchBio NextGen VC Forum in San Francisco, the firm’s Patents and Innovations Learning Library for in-house IP counsel, the latest episodes of the LaunchBio/Wilson Sonsini NextGen VC Podcast focused on life sciences investing, and the firm’s sponsorship of the National Inventors Hall of Fame Induction Ceremony, as well as select life sciences client highlights.
Newsletters
1.04.24
The Life Sciences Report – January 2024
This issue features articles on the firm’s Business Advisory Practice supporting Nervosave Therapeutics’ U.S. expansion; the USPTO’s forthcoming guidance on AI innovation protection; option pool sizes for life sciences companies; life sciences venture financings for clients in 2H 2022 and 1H 2023; and Congress’s attempts to improve medical diagnostics patent eligibility. It also includes a client interview with SonoThera CEO Kenneth Greenberg, an article on DOJ’s incentives for life sciences companies to self-disclose misconduct, and a Q&A with Ed Shenkan on decreasing risk from medical device concept to commercialization, as well as details on recent life sciences-focused NextGen VC Forums hosted by Wilson Sonsini and LaunchBio, the 28th annual Phoenix Conference and 2023 Life Sciences Investment Forum, and select life sciences client highlights.
Newsletters
6.07.23
The Life Sciences Report – June 2023
This latest issue features an article on Enliven Therapeutics’ reverse merger with Imara and concurrent financing, including an interview with Enliven co-founder and CEO Sam Kintz; a piece on trends in digital health following the end of the COVID-19 public health emergency; and an analysis of life sciences venture financings in which clients participated across the first and second halves of 2022. It also includes details on the life sciences-focused NextGen VC Forum hosted by Wilson Sonsini and LaunchBio, a preview of the U.S.-Japan Healthcare Connection’s trade mission and roadshow for healthcare companies, a recap of the firm’s inaugural 1L Life Sciences Summit, and select life sciences client highlights, among other content.
Client Highlights
3.15.22
Wilson Sonsini Advises Nalu Medical on $104 Million Equity Financing
On February 17, 2022, Nalu Medical, Inc., a private company focused on innovative and minimally invasive solutions for chronic neuropathic pain, announced a $104 million equity financing. The round was led by new investors MVM Partners and Gilde Healthcare. New investors Pura Vida Investments and Aperture Venture Partners, as well as existing investors Advent Life Sciences, Decheng Capital, Endeavour Vision, and Longitude Capital, also participated in the round. The proceeds from this financing are intended to be used for scaling commercial operations to accelerate growth, continued expansion of clinical evidence, and continuing product development, in addition to other general corporate purposes. Wilson Sonsini Goodrich & Rosati advised Nalu Medical on the transaction.
Newsletters
6.14.21
The Life Sciences Report – June 2021
In this issue, we feature articles on managing IP development and capture at growing medtech start-ups, life sciences venture financings in which firm clients participated during 2020, the U.S.-Japan Healthcare Connection's virtual conference on the coming revolution in healthcare, and the Biden administration's signing of two bipartisan bills that aim to promote drug competition and reduce prescription drug prices, as well as a summary of select recent life sciences client highlights.
Client Highlights
2.26.21
Wilson Sonsini Advises Simplify Medical in Its Acquisition by NuVasive
On February 24, 2021, NuVasive, Inc., the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, announced that it has acquired Simplify Medical, a privately held company and developer of the Simplify® Cervical Artificial Disc (Simplify Disc) for cervical total disc replacement (cTDR). Wilson Sonsini Goodrich & Rosati represented Simplify Medical in the transaction.
Newsletters
1.28.21
The Life Sciences Report - Winter 2021
The latest issue features a sampling of recent COVID-19-related client activity in which the firm has been involved, an article on life sciences venture financings in which firm clients participated in 2H 2019 and 1H 2020, an interview with Cyrano Therapeutics CEO Rick Geoffrion regarding the Early Feasibility Studies Program for medical device manufacturers, and an article authored by Voler Systems president Walt Maclay on common design mistakes made by medical device start-ups. In addition, the publication includes a recap of the MedTech Emerging Growth Companies 2020 Virtual Roadshow; an interview with Dr. Wasim Malik of Iaso Ventures; and a summary of other select recent life sciences client highlights.
Client Highlights
10.09.20
Wilson Sonsini Advises Avail Medsystems in $100 Million Series B
On October 7, 2020, Avail Medsystems, the medical technology company pioneering telemedicine for the procedure room (Procedural Telemedicine™), announced that it has raised $100 million in Series B funding led by D1 Capital Partners, with participation from 8VC and existing investors. Wilson Sonsini Goodrich & Rosati represented Avail Medsystems in the transaction.
Client Highlights
8.12.20
Wilson Sonsini Advises Limelight Health in $75 Million Acquisition by FINEOS
On August 10, 2020, FINEOS Corporation, a global market leader in core systems for life, accident, and health insurance, announced that it has entered into an agreement to acquire Limelight Health, a leading North American provider of quoting, rating, and underwriting solutions for group and voluntary employee benefits, for $75 million, subject to customary adjustments. The union will provide an end-to-end SaaS core product suite from quote, rate, and underwrite through to billing, policy administration, absence, and claims management for the global life, accident, and health industry. Wilson Sonsini Goodrich & Rosati represented Limelight Health in the transaction.
Newsletters
2.27.19
The Life Sciences Report: Winter/Spring 2019
February 27, 2019
This edition of Wilson Sonsini's Life Sciences Report includes the latest on life sciences and healthcare venture financings, in addition to an in-depth look at CFIUS compliance and mandatory filings. Plus, read about an alternative source of capital for medical tech companies in the U.S., and catch up on client highlights and upcoming industry events.
This edition of Wilson Sonsini's Life Sciences Report includes the latest on life sciences and healthcare venture financings, in addition to an in-depth look at CFIUS compliance and mandatory filings. Plus, read about an alternative source of capital for medical tech companies in the U.S., and catch up on client highlights and upcoming industry events.